secwatch.observer — SEC 8-K summary
======================================

Issuer:     20/20 Biolabs, Inc. (AIDX)
CIK:        0001139685
Form:       8-K
Filed at:   2026-08-17T20:05:37+00:00
Accession:  0001213900-26-090746
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

20/20 BioLabs Q2 revenue up 37% to $0.7M; OneTest revenue up 47%
----------------------------------------------------------------

- Q2 2026 total revenue $0.7M, up 36.5% YoY; OneTest revenue $0.7M, up 47.1%, 95.3% of total.
- Gross profit $0.3M, up 86.6%; gross margin 41.7% vs 30.5%.
- Net loss $1.5M vs $0.8M; cash $4.5M, up from $1.0M; convertible note debt eliminated.
- Vermont and Maryland firefighter programs expected to generate >$1.0M revenue through 2026; >35,000 firefighters tested by year-end.
- Raised $6.0M Series E preferred in H1 2026; up to $40M available; standstill with Streeterville.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1139685/000121390026090746/0001213900-26-090746-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1139685/000121390026090746/ea0302153-8k_2020bio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-090746

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer